A Vicious Circle of Clonal Haematopoiesis of Indeterminate Potential and Cardiovascular Disease

Carolin A. Ehlert; Ingo Hilgendorf

doi:10.1055/a-1576-4059

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 2021; 41(06): 443-446
DOI: 10.1055/a-1576-4059

Review Article

A Vicious Circle of Clonal Haematopoiesis of Indeterminate Potential and Cardiovascular Disease

Carolin A. Ehlert

¹Department of Cardiology and Angiology I, University Heart Center Freiburg – Bad Krozingen and Faculty of Medicine, University of Freiburg, Freiburg, Germany

,

Ingo Hilgendorf

¹Department of Cardiology and Angiology I, University Heart Center Freiburg – Bad Krozingen and Faculty of Medicine, University of Freiburg, Freiburg, Germany

²Institute for Experimental Cardiovascular Medicine, University Heart Center Freiburg – Bad Krozingen and Faculty of Medicine, University of Freiburg, Freiburg, Germany

› Institutsangaben

Abstract

Clonal haematopoiesis of indeterminate potential (CHIP) represents a recently identified overlap between cancer and cardiovascular disease (CVD). CHIP develops as a result of certain acquired somatic mutations that predispose to leukaemia, but clinically even more prevalent, associate with increased risk for CVD and CVD-related death. Experimental studies suggest a causal role for CHIP aggravating inflammatory processes in CVD, and recent epidemiologic and genetic studies indicate that classical CVD risk factors may increase the risk of acquiring CHIP driver mutations, thus fuelling a vicious circle. The potential mechanism underlying the associative link between CHIP and CVD and mortality has been the focus of a few recent excellent experimental and observational studies which are summarized and discussed in this concise non-systematic review article. These data support a pathomechanistic view of a spiralling vicious circle in which CHIP aggravates the inflammatory immune response in CVD, and CVD-driven elevated haematopoietic activity promotes CHIP development.

Zusammenfassung

Klonale Hämatopoese von unbestimmtem Potential (CHIP) stellt eine Überschneidung von Krebs- und kardiovaskulären Erkrankungen dar, die erst seit Kurzem Beachtung findet. CHIP entsteht infolge bestimmter erworbener somatischer Mutationen und prädisponiert für die Entwicklung von Leukämien. Aber klinisch häufiger ist die Assoziation mit einem erhöhten Risiko für kardiovaskuläre Erkrankungen und Tod. Experimentelle Studien weisen auf eine kausale Beziehung zwischen CHIP und einem verstärkten Entzündungsprozess bei kardiovaskulären Erkrankungen hin. Epidemiologische und genetische Studien suggerieren umgekehrt, dass die klassischen kardiovaskulären Risikofaktoren das Risiko für die Entwicklung somatischer CHIP-assoziierter Mutationen erhöhen und somit einen Teufelskreis antreiben könnten.

Keywords

clonal haematopoiesis - cardiovascular disease - somatic mutation

Schlüsselwörter

klonale Hämatopoese - kardiovaskuläre Erkrankung - somatische Mutation

Volltext

Referenzen

References
1 Steensma DP, Bejar R, Jaiswal S. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; 126 (01) 9-16
2 Genovese G, Kähler AK, Handsaker RE. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371 (26) 2477-2487
3 Arends CM, Galan-Sousa J, Hoyer K. et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia 2018; 32 (09) 1908-1919
4 Jaiswal S, Fontanillas P, Flannick J. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371 (26) 2488-2498
5 Calvillo-Argüelles O, Jaiswal S, Shlush LI. et al. Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review. JAMA Cardiol 2019; 4 (04) 380-387
6 Jaiswal S, Natarajan P, Silver AJ. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017; 377 (02) 111-121
7 Mas-Peiro S, Hoffmann J, Fichtlscherer S. et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur Heart J 2020; 41 (08) 933-939
8 Dorsheimer L, Assmus B, Rasper T. et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol 2019; 4 (01) 25-33
9 Assmus B, Cremer S, Kirschbaum K. et al. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. Eur Heart J 2021; 42 (03) 257-265
10 Natarajan P, Jaiswal S, Kathiresan S. Clonal hematopoiesis: somatic mutations in blood cells and atherosclerosis. Circ Genom Precis Med 2018; 11 (07) e001926
11 Fuster JJ, MacLauchlan S, Zuriaga MA. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017; 355 (6327): 842-847
12 Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ Res 2018; 123 (03) 335-341
13 Rauch PJ, Silver AJ, Gopakumar J. et al. Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and convergent macrophage phenotypes in mice. Blood 2018; 132 (Suppl. 01) 745
14 Fidler TP, Xue C, Yalcinkaya M. et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 2021; 592 (7853): 296-301
15 Khetarpal SA, Qamar A, Bick AG. et al. Clonal hematopoiesis of indeterminate potential reshapes age-related CVD: JACC review topic of the week. J Am Coll Cardiol 2019; 74 (04) 578-586
16 James C, Ugo V, Le Couédic JP. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434 (7037): 1144-1148
17 Edelmann B, Gupta N, Schnoeder TM. et al. JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. J Clin Invest 2018; 128 (10) 4359-4371
18 Fuchs TA, Brill A, Duerschmied D. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010; 107 (36) 15880-15885
19 Wolach O, Sellar RS, Martinod K. et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med 2018; 10 (436) eaan8292
20 Abplanalp WT, Mas-Peiro S, Cremer S, John D, Dimmeler S, Zeiher AM. Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure. JAMA Cardiol 2020; 5 (10) 1170-1175
21 Abplanalp WT, Cremer S, John D. et al. Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure. Circ Res 2021; 128 (02) 216-228
22 Heyde A, Rohde D, McAlpine CS. et al. Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. Cell 2021; 184 (05) 1348.e22-1361.e22
23 Bhattacharya R, Zekavat SM, Uddin MM. et al. Association of diet quality with prevalence of clonal hematopoiesis and adverse cardiovascular events. JAMA Cardiol 2021; 6 (09) 1069-1077
24 Haring B, Reiner AP, Liu J. et al. Healthy lifestyle and clonal hematopoiesis of indeterminate potential: results from the women's health initiative. J Am Heart Assoc 2021; 10 (05) e018789
25 van Deuren RC, Andersson-Assarsson JC, Kristensson FM. et al. Clone expansion of mutation-driven clonal hematopoiesis is associated with aging and metabolic dysfunction in individuals with obesity. bioRxiv 2021 https://doi.org/10.1101/2021.05.12.443095
26 Yvan-Charvet L, Pagler T, Gautier EL. et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010; 328 (5986): 1689-1693